Clinical treatment options in chronic lymphocytic carcinoma (CLL) are often limited due to fast occurring drug resistances. The specific TE of such tumours are lymph nodes, which harbour the proliferating pool of cancer cells. Here, different novel small molecules will be investigated in regard to their potential to overcome treatment resistance of CLL cells. One of them being a novel small molecule targeting the one-carbon metabolism, a pathway that is essential to support nucleotide synthesis. The project will take advantage of patient-derived cells, genetic mouse models and resistant cell lines.
|Acronym||CANBIO2 (Chloé Duculty)|
|Effective start/end date||1/01/23 → 31/12/26|
- FNR - Fonds National de la Recherche: €170,000.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.